SCHEMBL3207582

SCHEMBL3207582

CC1(C)C(=O)CN(Cc2ccccc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.56
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
GAA P10253 1/20 0.47
EPHX2 P34913 1/20 0.46
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
CTSG P08311 2/20 0.45
PRTN3 P24158 1/20 0.45
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD11B1 P28845 1/20 0.41
F2 P00734 1/20 0.41
PLG P00747 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6341183 0.83 DDB1 (0.55) ELANEKMT2AMEN1GAAEPHX2
SCHEMBL1189753 0.83 KMT2A (0.61) ELANEKMT2AMEN1EPHX2DDB1
SCHEMBL12491711 0.80 KMT2A (0.67) ELANEKMT2AMEN1EPHX2DDB1
SCHEMBL16835494 0.80 KMT2A (0.67) ELANEKMT2AMEN1EPHX2DDB1
SCHEMBL23580689 0.80 ELANE (0.45) ELANEKMT2AMEN1GAAEPHX2
SCHEMBL23580081 0.79 GAA (0.59) ELANEKMT2AMEN1GAACTSG
SCHEMBL27020595 0.76 ELANE (0.39) ELANEKMT2AMEN1GAAEPHX2
SCHEMBL3127344 0.76 EPHX2 (0.54) ELANEKMT2AMEN1GAAEPHX2
SCHEMBL13484401 0.76 ELANE (0.56) ELANEKMT2AMEN1GAAEPHX2
SCHEMBL10870338 0.75 ELANE (0.55) ELANEKMT2AMEN1GAAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100036120-A1 NOVEL METHOD FOR SYNTHESIS OF 1,4-MORPHOLINE-2,5-DIONES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2010-02-11 US disclosed
US-20100036120-A1 NOVEL METHOD FOR SYNTHESIS OF 1,4-MORPHOLINE-2,5-DIONES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2010-02-11 US disclosed
US-20100036120-A1 NOVEL METHOD FOR SYNTHESIS OF 1,4-MORPHOLINE-2,5-DIONES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2010-02-11 US disclosed
WO-2007085729-A2 NOVEL METHOD FOR SYNTHESIS OF 1,4-MORPHOLINE-2,5-DIONES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036120-A1 NOVEL METHOD FOR SYNTHESIS OF 1,4-MORPHOLINE-2,5-DIONES CBR1, CBR3, NOX4 ELANE 4632/4885KMT2A 1823/4885MEN1 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.